-
Most Recent
Search Results
240 results for MER
Novavax Stock Is Poised to Climb Further
NVAX stock seems positioned for further gains with the firm’s vaccine deliveries set to begin in early 2022.
Novavax: Big Market Potential, Meaningful Stock Upside
Even after a 5,690% gain, NVAX stock looks positioned for further upside with the firm’s focus on bringing vaccines to low-income countries.
Inovio Pharma’s Next Clinical Results Will be Binary for INO Stock
Inovio Pharma’s next clinical results will be a binary event for INO Stock. It will rise or fall based on its Phase 1 results due…
Add Inovio Stock to Your High-Growth Biotech Holdings
You can call INO a coronavirus stock, but it’s really much more than that.
Inovio Is Still Hot as the Coronavirus Spreads
INO stock still has some serious upside, thanks to its INO-4800. Inovio’s coronavirus vaccine takes the lead and is in preclinical trials.
Gilead’s Cash and the Coronavirus Make GILD Stock Look Cheap
Gilead Sciences rose to prominence with its hepatitis C drug. Now GILD stock is soaring on hopes for a coronavirus treatment.
Focus on iBio’s Tech, Not Its Coronavirus Story
IBIO stock shot up in March on news that it might produce a coronavirus vaccine. However, its at-scale production tech is more interesting.
iBio Stock Is Too Risky
IBIO stock gets attention because of iBio’s foray into treating the coronavirus, but investors who want that exposure should look elsewhere.
Don’t Buy Inovio Stock on Hopes for a Vaccine
Coronavirus hysteria on Wall Street is temporary. When it passes, INO stock could turn into a “look out below” situation.
Bet on INO Stock Beyond Its Promising Covid-19 Vaccine Developments
Inovio just launched its Phase 1 trials of INO-4800 for a vaccine. Should all go according to plan, INO could run to at least $20…
Gilead Sciences Pins Its Hopes on Remdesivir
Clinical trial results for Gilead’s remdesivir should come this month. If it’s effective, GILD stock could explode higher on the news.
Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers
IBIO stock has been acting like a potential COVID-19 vaccine producer, but it lacks contracts with leading providers and its own work remains at a…
Novavax Is the Ultimate Coronavirus Stock
Novavax has failed at late-stage clinical trials before, but if its COVID-19 vaccine even has 50% efficacy it could open up a huge global opportunity.
4 Big, Safe Dividend Plays for the Long Haul
Dividend ETFs are popular with investors, as they seek better performance than bonds provide. Here are four ETFs for the long haul.
5 Best Vanguard Funds to Buy for Target Date 2030 Retirement
You’re going to need some added oomph if you’ve got roughly 15-20 years before retirement. Here’s a look at some of the best Vanguard funds…
3 Cult-Like Stocks to Buy for Long-Term Gains
There are stocks and then there are cult-like stocks. These three are in the latter category for many reasons including making you money.
Capital Destruction Paves Way for Further Losses
Once in a lifetime events are piling up so fast that we are going to need several lifetimes to absorb them. Someday we’ll look back…
Will the Support Hold?
Our indicators and charts are telling us that the market is testing its support at Dow 8,000 and S&P 500 800.
Novavax Stock Rises as UK Covid Vax Okay Sought, Other Growth Anticipated
Novavax stock offers a unique opportunity to invest in a late stage biotech built on cutting-edge vaccine technology, NVAX stock has surged on its Covid-19…
Moderna Faces Tough Threats in the Short and Long Term
Moderna is facing meaningful short-term and longer-term threats. As a result, investors should sell MRNA stock at this point.
6 – 10 of 240 results
